Impact of malignancy on outcomes in European patients with atrial fibrillation A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry /
The management of patients with atrial fibrillation (AF) and malignancy is challenging given the paucity of evidence supporting their appropriate clinical management.To evaluate the outcomes of patients with active or prior malignancy in a contemporary cohort of European AF patients.Patients enrolle...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2022
|
| Sorozat: | EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
52 No. 7 |
| Tárgyszavak: | |
| doi: | 10.1111/eci.13773 |
| mtmt: | 34108414 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/38935 |
| Tartalmi kivonat: | The management of patients with atrial fibrillation (AF) and malignancy is challenging given the paucity of evidence supporting their appropriate clinical management.To evaluate the outcomes of patients with active or prior malignancy in a contemporary cohort of European AF patients.Patients enrolled in the EURObservational Research Programme in AF General Long-Term Registry were categorized into 3 categories: No Malignancy (NoMal), Prior Malignancy (PriorMal) and Active Malignancy (ActiveMal). The primary outcomes were all-cause death and the composite outcome MACE.A total of 10 383 patients were analysed. Of these, 9597 (92.4%) were NoMal patients, 577 (5.6%) PriorMal and 209 (2%) ActiveMal. Lack of any antithrombotic treatment was more prevalent in ActiveMal patients (12.4%) as compared to other groups (5.0% vs 6.3% for PriorMal and NoMal, p < .001). After a median follow-up of 730 days, there were 982 (9.5%) deaths and 950 (9.7%) MACE events. ActiveMal was independently associated with a higher risk for all-cause death (HR 2.90, 95% CI 2.23-3.76) and MACE (HR 1.54, 95% CI 1.03-2.31), as well as any haemorrhagic events and major bleeding (OR 2.42, 95% CI 1.49-3.91 and OR 4.18, 95% CI 2.49-7.01, respectively). Use of oral anticoagulants was not significantly associated with a higher risk for all-cause death or bleeding in ActiveMal patients.In a large contemporary cohort of AF patients, active malignancy was independently associated with all-cause death, MACE and haemorrhagic events. Use of anticoagulants was not associated with a higher risk of all-cause death in patients with active malignancies. |
|---|---|
| Terjedelem/Fizikai jellemzők: | 16 |
| ISSN: | 0014-2972 |